Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Garman, K. Munroe, S. Richards (2004)
Methotrexate reduces antibody responses to recombinant human α‐galactosidase A therapy in a mouse model of Fabry diseaseClinical & Experimental Immunology, 137
D. Germain (2002)
Fabry disease: recent advances in enzyme replacement therapyExpert Opinion on Investigational Drugs, 11
M. Beck, R. Ricci, U. Widmer, F. Dehout, A. Lorenzo, C. Kampmann, A. Linhart, G. Sunder-Plassmann, G. Houge, U. Ramaswami, A. Gal, A. Mehta (2004)
Fabry disease: overall effects of agalsidase alfa treatmentEuropean Journal of Clinical Investigation, 34
G. Linthorst, C. Hollak, W. Donker‐Koopman, A. Strijland, J. Aerts (2004)
Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta.Kidney international, 66 4
D. Germain, S. Waldek, M. Banikazemi, D. Bushinsky, J. Charrow, R. Desnick, P. Lee, T. Loew, A. Vedder, R. Abichandani, W. Wilcox, N. Guffon (2007)
Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.Journal of the American Society of Nephrology : JASN, 18 5
P. Whitfield, J. Calvin, S. Hogg, E. O'Driscoll, D. Halsall, K. Burling, G. Maguire, N. Wright, T. Cox, P. Meikle, P. Deegan (2005)
Monitoring enzyme replacement therapy in Fabry disease—Role of urine globotriaosylceramideJournal of Inherited Metabolic Disease, 28
RJ Desnick, YA Ioannou, CM Eng (2001)
The metabolic and molecular basis of inherited disease
A. Linhart, C. Kampmann, J. Zamorano, G. Sunder-Plassmann, M. Beck, A. Mehta, P. Elliott (2007)
Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey.European heart journal, 28 10
K MacDermot, A. Holmes, Alec Miners (2001)
Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier femalesJournal of Medical Genetics, 38
S Gupta, M Ries, S Kotsopoulos (2005)
The relationship of vascular glycolipid storage to clinical manifestations of Fabry diseaseMedicine, 84
R. Schiffmann, M. Ries, Margaret Timmons, J. Flaherty, R. Brady (2006)
Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 21 2
Surya Gupta, M. Ries, S. Kotsopoulos, R. Schiffmann (2005)
The Relationship of Vascular Glycolipid Storage to Clinical Manifestations of Fabry Disease: A Cross-Sectional Study of a Large Cohort of Clinically Affected Heterozygous WomenMedicine, 84
C. Eng, N. Guffon, W. Wilcox, Dominique Germain, P. Lee, S. Waldek, L. Caplan, G. Linthorst, R. Desnick (2001)
Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.The New England journal of medicine, 345 1
P. Deegan, A. Baehner, M. Romero, D. Hughes, C. Kampmann, M. Beck (2005)
Natural history of Fabry disease in females in the Fabry Outcome SurveyJournal of Medical Genetics, 43
K. Macdermot, A. Holmes, Alec Miners (2001)
Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous malesJournal of Medical Genetics, 38
F. Baehner, C. Kampmann, C. Whybra, E. Miebach, C. Wiethoff, M. Beck (2003)
Enzyme replacement therapy in heterozygous females with Fabry disease: Results of a phase IIIB studyJournal of Inherited Metabolic Disease, 26
R. Desnick (2001)
α-Galactosidase A deficiency. Fabry disease
F. Breunig, F. Weidemann, J. Strotmann, A. Knoll, C. Wanner (2006)
Clinical benefit of enzyme replacement therapy in Fabry disease.Kidney international, 69 7
R. Schiffmann, J. Kopp, H. Austin, S. Sabnis, D. Moore, T. Weibel, J. Balow, R. Brady (2001)
Enzyme replacement therapy in Fabry disease: a randomized controlled trial.JAMA, 285 21
William Wilcox, M. Banikazemi, N. Guffon, Steve Waldek, Philip Lee, G. Linthorst, Robert Desnick, Dominique Germain (2004)
Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.American journal of human genetics, 75 1
Collecting data systematically about adverse effects which might be caused by drugs is essential for orphan diseases in order to detect potential adverse effects which cannot be suspected at first.
European Journal of Clinical Pharmacology – Springer Journals
Published: Jan 26, 2008
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.